3190 results for «881»
3190 results
TEER in complex tricuspid regurgitation - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.
Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.
LIVE Educational Case...
Hot topics and evidence on structural interventions in 2025 and 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...
Prevention and management of TAVI complications
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
Guidelines update
15 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...
Future devices and techniques for structural heart disease
15 Feb 2026 – From PCR Tokyo Valves 2026
This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.
One-month ticagrelor monotherapy after PCI in acute coronary syndromes: Principal results from the double-blind, placebo-controlled Ultimate DAPT trial
07 Apr 2024
Elad Asher provides his take on the ULTIMATE-DAPT Trial results which Gregg W Stone presented at ACC.24 in Atlanta.
Author
FAVOR III China: Angiographic quantitative flow ratio-guided coronary intervention - a multicentre, randomised, sham-controlled trial
04 Nov 2021
Nicola Ryan provides her take on this investigator initiated, multicentre, randomised, blinded, sham controlled trial compares clinical outcomes of QFR versus angiography guided strategies for the treatment of non-critical lesions in patients with stable or unstable angina or MI at least 72 hours prior to screening....
Author
Mid-term echocardiographic outcomes following transapical mitral valve replacement: Updates from the Intrepid Pilot Study
19 Sep 2022
Pamela Gatto provides her take on the Intrepid Global Pilot Study which was presented by Renuka Jain at TCT Congress 2022.
Author
Transcatheter aortic valve replacement in small aortic annuli: Results from the FRANCE-TAVI registry
17 Sep 2022
Mirvat Alasnag provides her take on the outcomes of small annuli sub-study from the FRANCE-TAVI Registry which included 1,195 patients. This trial was presented by Walid Ben-Ali at TCT 2022.
Author
